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What is already known on the subject? 
 Urocortins 2 and 3 are emerging therapies for treating heart failure.  
 Urocortins 2 and 3 reduce peripheral vascular resistance and increase cardiac 
output in both health and disease. 
 
What this study adds? 
 This is the first direct head-to-head comparison of urocortin 2 and urocortin 3 in 
man. 
 These data provide further evidence that urocortin 2 and urocortin 3 hold major 
potential for the treatment of heart failure.  
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Abstract 
 
Aims: Urocortin 2 and urocortin 3 may play a role in the pathophysiology of heart failure and 
are emerging therapeutic targets. We aimed to examine the local and systemic cardiovascular 
effects of urocortin 2 and urocortin 3 in healthy subjects and patients with heart failure. 
Methods: Patients with heart failure (n=8) and age and sex-matched healthy subjects (n=8) 
underwent bilateral forearm arterial blood flow measurement using forearm venous occlusion 
plethysmography during intra-arterial infusions of urocortin 2 (3.6-36 pmol/min), urocortin 3 
(360-3600 pmol/min) and substance P (2-8 pmol/min). Heart failure patients (n=9) and 
healthy subjects (n=7) underwent non-invasive impedance cardiography during incremental 
intravenous infusions of sodium nitroprusside (573-5730 pmol/kg/min ), urocortin 2 (36-360 
pmol/min ), urocortin 3 (1.2-12 nmol/min) and saline placebo.  
Results: Urocortin 2, urocortin 3 and substance P induced dose-dependent forearm arterial 
vasodilatation in both groups (p<0.05 for both) with no difference in magnitude of 
vasodilatation between patients and healthy subjects. During systemic intravenous infusions, 
urocortin 3 increased heart rate and cardiac index and reduced mean arterial pressure and 
peripheral vascular resistance index in both groups (p<0.01 for all). Urocortin 2 produced 
similar responses to urocortin 3, although increases in cardiac index and heart rate were only 
significant in heart failure (p<0.05) and healthy subjects (p<0.001), respectively.  
Conclusion:  Urocortins 2 and 3 cause vasodilatation, reduce peripheral vascular resistance 
and increase cardiac output in both health and disease. These data provide further evidence to 
suggest that urocortins 2 and 3 continue to hold promise for the treatment of heart failure.  
 
 
Keywords: Cardiac; urocortin; Heart Failure; Inotrope; Vasodilator. 
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Introduction 
There are almost six million people living with heart failure in the USA. This comes at an 
annual cost to the US economy of over $30 billion.[1] Despite many evidence-based 
therapies for patients with chronic heart failure, treatments for acute heart failure are limited, 
less well developed and have not been shown to improve clinical outcomes. Indeed the use of 
inotropic agents has been associated with harm.[2-4] However, the tentative but promising 
improvements in clinical outcome seen with serelaxin in the recent RELAX-AHF study[5] 
has renewed enthusiasm for the assessment of novel vasoactive mediators in this important 
patient group. 
The urocortins are an endogenous peptidic hormone group comprising urocortin 1, urocortin 
2 and urocortin 3 with vasodilator, inotropic and lusitropic effects. [6] Urocortins 2 and 3 
counteract many of the effects of corticotrophin-releasing hormone (CRH), [7-10] and act on 
the CRH-receptor 2 (CRH-R2), a G-protein coupled receptor that is expressed abundantly in 
the heart and peripheral vasculature. [11,12] Urocortin 2 causes vasodilatation in healthy 
volunteers, augments cardiac output and reduces vascular resistance in healthy humans, 
patients with acute decompensated, and also chronic stable, heart failure. [13-16] 
A recombinant acetate salt of urocortin 3 (JNJ-39588146 [recombinant stresscopin]), 
improved cardiac output whilst reducing vascular resistance in a multi-centre study of 
patients with chronic stable heart failure. [17] We recently demonstrated that Urocortins 2 
and 3 increase forearm blood flow in young healthy volunteers. [15]To date, no clinical study 
has separated the regional from systemic effects of urocortins 2 and 3 in heart failure, or 
conducted a direct head to head comparison of their effects. 
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We aimed to evaluate and compare the local and systemic cardiovascular effects of urocortins 
2 and 3 in patients with heart failure and healthy subjects by assessing (i) local forearm 
arterial blood flow using venous occlusion plethysmography, and (ii) cardiac output and 
vascular resistance using thoracic bioimpedance cardiography. We hypothesized that 
urocortins 2 and 3 would cause vasodilatation, reduced peripheral vascular resistance and 
increased cardiac output in both healthy subjects and patients with heart failure. 
 
Methods 
Both studies were approved by the local research ethics committee (South East Scotland REC 
01) and carried out in accordance with the Declaration of Helsinki. Written informed consent 
was obtained from all participants prior to the study. 
Study participants 
Patients with heart failure were eligible if they were aged 18-80 years, New York Heart 
Association (NYHA) symptom class II-III and had echocardiographically confirmed left 
ventricular ejection fraction < 35% with left ventricular end diastolic diameter > 5.5 cm. 
Patients were required to be receiving maximally tolerated doses of angiotensin-converting 
enzyme inhibitor and beta-blocker therapies for at least 3 months. Healthy subjects had no 
significant previous medical history and were on no regular medications. Exclusion criteria 
for both groups included systolic blood pressure >190 mmHg or <90 mmHg, 
hemodynamically significant valvular heart disease and other severe or significant co-
morbidities including bleeding diathesis, renal or hepatic failure, anemia or recent 
infective/inflammatory conditions. Women of child bearing potential were also excluded.  
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Protocol A: Local vascular study 
This was a randomized study (Figure 1a) of 8 patients with heart failure and 8 age and sex-
matched healthy subjects. Subjects attended once each to receive incremental intra-arterial 
infusions of urocortin 2 (3.6, 12, 36 pmol/min, molecular weight 4450.3g/mol) urocortin 
3(360, 1200, 3600 pmol/min, molecular weight 4137.9g/mol) and substance P (2, 4, 8 
pmol/min [control endothelium-dependent vasodilator]) for six min at each dose with a 30 
min washout period between agents.  
Forearm venous occlusion plethysmography studies were performed with the subject lying 
supine, in a quiet, temperature-controlled room (22-25°C). Participants fasted for 4 hours 
prior to the study and refrained from alcohol and caffeine for 24 hours prior to the study. 
Venous cannulae (17G) were inserted into large subcutaneous veins in the antecubital fossae 
of both arms at the start of the study to facilitate periodic venous sampling. Heart rate and 
blood pressure were monitored at regular intervals throughout the study with a semi-
automated oscillometric sphygmomanometer (Omron 705IT). Participants underwent 
brachial artery cannulation of the non-dominant forearm with a 27 standard wire-gauge steel 
needle for agent infusion. Forearm blood flow was measured in the infused and non-infused 
forearms using bilateral venous occlusion plethysmography as described previously. [18,19]  
Protocol B: Systemic Study 
This was a randomized, double-blind, placebo controlled cross-over study (Figure 1b). Three 
patients with heart failure and three volunteers participants were involved in both studies. 
Patients with heart failure (n=9) and healthy subjects (n=7) were recruited. Participants had 
venous cannulae inserted into both antecubital fossae, and attended on two occasions, 
receiving intravenous infusions of saline (placebo) or SNP (573, 1909, 5730 pmol/kg/min) 
followed by either urocortin 2 (36, 108, 360 pmol/min) or urocortin 3 (1.2, 3.6, 12 nmol/min). 
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On the second visit, participants received the 2 remaining agents not administered on visit 1. 
Each agent was given in 3 ascending doses for 10 min at each dose. A one-hour saline 
washout was given between agents and a further 30 min of saline washout was administered 
after the cessation of the second agent.  
 
Hemodynamic Monitoring 
Hemodynamic measurements were recorded throughout the study. Cardiac output, blood 
pressure and stroke volume were recorded using non-invasive thoracic impedance 
cardiography (NCCOM3-R7, BioMed, CA, USA or Cardioscreen 1000, Medis, Germany) 
and oscillometric sphygmomanometry (Omron HEM-705CP, Omron, Matsusaka, Japan). 
Values were indexed to body surface area where appropriate and peripheral vascular 
resistance index was calculated using recorded measurements (PVRI = MAP/CI). 
 
Safety: 
Study stopping criteria were in place to ensure participant safety. Criteria included a drop in 
diastolic blood pressure of >25 mmHg, fall in heart rate below 50 bpm or rise above 120 bpm, 
at the request of the participant, attending nurse or the attending physician.  
 
Venous sampling 
Baseline blood samples were drawn for assessment of full blood count, renal function, 
glucose and cholesterol concentrations at the start of each study. The local clinical 
biochemistry and hematology reference laboratories performed analysis.  
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Data analysis and Statistics 
Data were collected in a double blind fashion for both studies. Data were analysed, where 
appropriate, by analysis of variance (ANOVA; one-way and two-way with repeated measures 
where appropriate). All results in figures are expressed as mean ± SEM. All statistical 
analysis was performed with GraphPad Prism, version 6 (GraphPad Software, San Diego, 
CA). Statistical significance was taken as two-sided P<0.05. 
RESULTS 
Patients with heart failure and healthy subjects recruited were predominantly male and 
middle-aged. Heart failure patients had greater BMI compared to healthy subjects. 
(Participant characteristics are shown in Table 1). Patients with heart failure were receiving 
maintenance heart failure therapy. Patients and volunteers were age and sex matched in 
Protocol A, and age matched alone in protocol B. Three patients with heart failure and three 
volunteers participants were recruited to both studies. 
Protocol A – Vascular Study 
The intra-brachial infusion of all three drugs was well tolerated with no adverse effects. Intra-
brachial infusion of urocortin 2 and 3 produced localised, self-limiting forearm flushing and 
some facial flushing in both groups of participants as noted in previous studies. [15] 
 
Urocortin 2, urocortin 3 and substance P all evoked dose-dependent forearm arterial 
vasodilatation in both participant groups (mean changes across the 3 doses [95%CI] from 
baseline as follows; Urocortin 2: +60% [9-111] p<0.05, +72% [21-123] p<0.01; Urocortin 3: 
+167% [100-237] p<0.0001, +151% [82-219] p<0.0001; Substance P: +227% [130-326] 
p<0.0001, +155% [57-253] p<0.001 for healthy controls and heart failure patients 
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respectively; Figure 2a). There were no significant differences in changes in forearm blood 
flow between heart failure patients and healthy subjects (urocortin 2; +12% [-40 to 63%] 
p=0.84, urocortin 3; -18% [-86 to +50%], p=0.80; Substance P; -72% [-170-+26%] p+0.19).  
 
Blood pressure and heart rate remained unchanged in both groups in response to urocortin 2 
and substance P. At the highest dose, urocortin 3 induced a transient tachycardia compared to 
baseline in both groups (heart failure - +14.9bpm [20.9 to 8.9], healthy volunteers -  
+21.3mmHg [27.3 to 15.3] both p<0.0001) that was accompanied by a drop in systolic (-
17.4mmHg [-7.9 to -26.9], p<0.0001) and diastolic blood pressure in patients with heart 
failure (-8.4mmHg [-3.5 to -13.3], p<0.001) and a drop in diastolic blood pressure alone in 
healthy subjects (-12.4mmHg [-7.5 to -17.3], p<0.0001, Figure 2b). Non-infused forearm 
blood flow remained unchanged throughout the study (data not shown). 
 
Protocol B – Systemic Study  
Participants displayed hypotension at the higher doses of SNP initially administered in the 
study (17.2 nmol/kg/min), frequently reaching study-stopping criteria.  A dose reduction to 
SNP (maximum dose of 5730 pmol/kg/min) was made after 2 healthy subjects completed the 
study. For the urocortins, hypotension reaching study-stopping criteria was met in 1 heart 
failure patient for urocortin 2, and 2 heart failure patients and 1 healthy subject for urocortin 
3. Participants described dose-dependent symptoms of tachycardia and a warm sensation with 
both urocortins, but there were no significant adverse events attributable to either urocortin 2 
or urocortin 3. Full blood count and serum biochemistry was unchanged between the two 
study visits (Table 1). 
Urocortin 2 had no significant effect on cardiac index in healthy subjects and heart rate in 
heart failure patients when compared to saline placebo (p>0.05 for both, see Figure 3 and 
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Table 2 for results). Otherwise urocortin 2 and urocortin 3 increased cardiac index and heart 
rate, and reduced mean arterial pressure and peripheral vascular resistance index in both 
patients with heart failure and healthy subjects (p<0.05 for all). There was no effect of either 
urocortin 2 or urocortin 3 on stroke volume (p>0.05 for both). 
At the doses used, urocortin 3 caused greater mean increases than urocortin 2 in cardiac index 
(+13.4 [+4.1 to +22.6], p<0.01) and heart rate (+11.0 [+2.9 to +19.2], p<0.01), and greater 
mean reductions in mean arterial pressure (+4.4 [0.0 to +8.7], p<0.05) and peripheral vascular 
resistance index (+11.2 [2.2 to +20.1], p<0.01) in patients with heart failure. No such 
haemodynamic differences existed between urocortin 2 and urocortin 3 in healthy subjects.  
No haemodynamic differences existed between participant groups for both urocortin 2 and 
urocortin 3 (p>0.05 for all). Following cessation of the intravenous infusions, hemodynamic 
variables returned to baseline after 40–60 min (for example, cardiac index, Figure 4). Over 
the infusion and washout period, urocortin 3 again caused a greater increase in cardiac output 
(p<0.0001) than urocortin 2 in patients with heart failure but not in healthy subjects (p=0.48). 
  
Discussion 
For the first time, we report the local vascular and systemic effects of urocortins in both 
patients with heart failure and healthy subjects. We demonstrate that both urocortin 2 and 
urocortin 3 increase cardiac index and reduce peripheral vascular resistance, and their 
parenteral administration is feasible, safe and well tolerated. We conclude this hemodynamic 
profile suggests that urocortins 2 and 3 hold major potential for the treatment of acute heart 
failure.  
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Forearm venous occlusion plethysmography combined with intra-arterial cannulation allows 
the assessment of local, sub-systemic vasomotor effects of peptides without exerting a 
systemic response. This is particularly useful in the study of novel compounds, such as 
urocortin 2 and urocortin 3. We have previously demonstrated that urocortin 2 and 3 cause 
vasodilatation in healthy subjects and that is in part mediated by endothelium-dependent 
factors such as nitric oxide and endothelium derived hyperpolarizing factor [15].  Impaired 
endothelial function is a recognized feature and an independent predictor of adverse outcome 
in patients with heart failure.[20-24] There is therefore a theoretical concern that urocortin 
would be less effective in patients with heart failure because of this concomitant endothelial 
dysfunction. However, we demonstrate that urocortin 2 and urocortin 3 evoked normal 
forearm arterial vasodilatory responses in our patients with heart failure. This suggests that 
either endothelial dysfunction does not have a meaningful impact on the actions of urocortin 
or our subjects did not have significant endothelial dysfunction. Interestingly, our patients did 
not demonstrate impaired substance P induced vasodilatation suggesting preserved 
endothelial function. This may reflect that the patients studied had stable heart failure 
symptoms and were well-treated and receiving optimal medical therapy. Whether similar 
findings would be observed in patients with decompensated heart failure remains to be 
established. 
 
During local intra-arterial infusions of the urocortins, we were not anticipating observing any 
major changes in hemodynamic variables in either group. However, we found dose-related 
increases in heart rate and falls in diastolic blood pressure, especially with urocortin 3 in 
healthy subjects. This suggests that at the doses used here, we had systemic spill over of 
urocortin such that we achieved vasoactive blood concentrations outwith the forearm. The 
doses where systemic systemic spill over was seen helped guide the dosing regime used in 
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protocol B. We have seen systemic spill over previously with other compounds such as 
substance P [25], and this is heralded by systemic flushing and rises in the contralateral non-
infused forearm blood flow. However, here we observed no change in contralateral non-
infused forearm blood flow although subjects did develop some skin flushing. This suggests 
that other vascular beds, such as the dermal and splanchnic circulation, are more sensitive to 
the actions of the urocortins than the forearm circulation. The increase in heart rate at the 
highest dose of urocortin 3 was less pronounced in patients with heart failure, and this was 
likely due to concomitant beta-blocker therapy. Furthermore the associated lower systolic and 
diastolic blood pressures in this group may be explained by a relative lack of compensatory 
tachycardia response to vasodilatation in these patients.   
 
During systemic intravenous infusions, we observed increases in cardiac output with both 
urocortins. This increase in cardiac output is likely to occur in response to the systemic 
vasodilatation induced by the urocortins. Although there was no change in stroke volume for 
either urocortin, this is not is direct measurement of inotropy, and we cannot exclude a direct 
inotropic effect of urocortin on the heart, as previously seen with Urocortin 2 in rodents. [26] 
At the doses we administered, urocortin 3 exerted more marked hemodynamic effects than 
urocortin 2 in patients but not healthy subjects. This may reflect the differences in doses we 
employed, but may also reflect important differences between these two agents. This needs 
further exploration to determine which urocortin subtype is the most promising for clinical 
therapeutic development. 
Differences in biological effects between the urocortins can be explained by the structural 
differences that exist between the two agents, generating conformational changes in the G 
protein coupled receptor, in turn altering secondary messenger systems that are responsible 
for creating the biological effects seen. However it may not be this simple and there may be 
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other systems involved. Promising preclinical studies suggest a role for the urocortins in the 
inhibition of cardiac sympathetic nerve activity [SNA] [27,28], often overactive in patients 
with heart failure. Although Ucn2 has been reported to increase skeletal muscle SNA in 
humans, [29] this should not necessarily be seen as a discrepant finding as SNA responses 
typically are regionally differentiated. 
Increases in heart rate have not been reported in recent studies with urocortin 2/stresscopin, 
[16,17] however higher doses of urocortin 2, [14] comparable to the doses we have used here, 
saw similar increases in heart rate.  
There may be concern regarding the clinical use of a heart failure therapy that is both 
positively chronotropic and inotropic. This combination of effects might predispose to 
increased myocardial oxygen consumption and potential arrhythmia, particularly in patients 
with coronary artery disease. We observed no episodes of arrhythmia or adverse effects in 
our study, and indeed urocortin 2 has been shown to have anti-arrhythmic effects that would 
be hugely beneficial in treating this group of patients. [30] [31] However, our infusions were 
brief, and adverse effects may be seen with longer infusions or in those patients with 
decompensated heart failure. In addition, avoidance of significant hypotension remains an 
important consideration, especially in patients with already low perfusion pressure or renal 
impairment. Results from our study suggest that dose titration during administration may be 
needed to optimize cardiac output and vasodilatory responses, whilst avoiding the unwanted 
effects of significant tachycardia or hypotension.  
Study Limitations 
This study included only patients with stable heart failure who were prescribed evidence-
based heart failure therapy that may have affected the response of these agents. However, 
there was no evidence of diminished effect with concomitant medical therapy in patients with 
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heart failure. We did not include patients with acute decompensated heart failure, but we did 
compare to healthy control subjects, not used in a similar sized study with urocortin 2.[14] 
Although our results cannot be extrapolated to the setting of acute heart failure, there appears 
to be no reason why the beneficial effects seen in this study cannot be replicated in the acute 
heart failure setting provided an appropriate, controlled dosing regime is used. Furthermore 
studies using Urocortin 2, and derivatives thereof, in the acute setting have already been 
carried out successfully. There does however remain a clear need for urocortin 3 to be trialed 
in this group of patients. 
We observed increases in cardiac index in protocol B, but it should be reinforced that this 
study was not designed to compare the relative contributions of chonotropy, inotropy and 
vasodilatation to the changes in cardiac index we recorded. Invasive studies would be 
required for this. Furthermore, the molar concentrations of urocortin 2 and urocortin 3 at each 
dose were different, and differences in efficacy may reflect the differences in dose used, and 
not true differences in potency.  
Finally although there was no change in stroke volume for either agent, we did not conduct 
invasive hemodynamic monitoring which would be required for assessment of true inotropy, 
and also useful for assessment of pulmonary capillary wedge pressure (PCWP). Surprisingly 
two recent studies did not detect a statistically significant reduction in PCWP in patients with 
heart failure with either urocortin 2/stresscopin, [16,17] however a clear trend toward a 
reduction in PCWP was seen in both studies.  
 
Conclusion: 
We demonstrate that both urocortin 2 and urocortin 3 increase cardiac index and reduce 
peripheral vascular resistance. Their parenteral administration was feasible, safe and well 
tolerated. We conclude that these data provide further evidence suggesting urocortin 2 and 
urocortin 3 continue to hold promise for the treatment of heart failure. 
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Figure 1a : Schematic representation of study protocol A – vascular study. 
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Figure 1b: Schematic representation of study protocol B – systemic study.  
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A – Forearm Blood Flow 
 
B – Systemic Haemodynamic Responses 
   
Figure 2: Haemodynamic responses during local administration of urocortin 2, urocortin 3 
and Substance P (Protocol A). 
 
A: Percentage change in forearm arterial blood flow to urocortin 2 (3.6-36 pmol/min), 
urocortin 3 (360-3600 pmol/min) and substance P (2-8 pmol/min) in patients with heart 
failure (red) and in healthy subjects (black). B: Non-invasive systemic hemodynamic 
responses to intra-arterial urocortin 2 (red), urocortin 3 (blue) and substance P (green) in 
healthy subjects (left) and patients with heart failure (right). (****=p,0.0001,**=p<0.01, 
*=p<0.05). 
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Figure 3: Changes in hemodynamic responses from baseline following systemic infusion 
(Protocol B). 
 
Hemodynamic responses to infusions of  urocortin 2, urocortin 3 and SNP in healthy subjects 
(black) and patients with heart failure (red) at Doses 1-3 (D1-D3). * represents significant 
differences to saline placebo (not shown) across the 3 doses (see Table 2). ^ represents 
significant differences between participant groups.  (****=p<0.0001, ***=p<0.001, 
**=p<0.01, *=p<0.05; ^^=p<0.01).  
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Figure 4: Duration of hemodynamic response (mins) to intravenous urocortin 2 and urocortin 
3 (Protocol B). 
 
Effects of urocortin 2 (red) and urocortin 3 (blue) last 40-60 minutes after cessation of Dose 3 
(D3) before returning to baseline. At the doses used, urocortin 3 caused a greater increase in 
cardiac output compared to urocortin 2 in patients with heart failure (p<0.0001) but not 
healthy subjects (p=0.48). 
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Table 1: Participant Characteristics for Protocol A and B. 
 
 
 
N (%), mean±SD, median [interquartile range] 
 Protocol A  Protocol B  
 Heart 
failure 
patients 
(n=8)  
  
Healthy 
Subjects 
(n=8) 
 Heart 
failure  
patients 
(n=9) 
Healthy 
Subjects 
(n=7) 
 
Age 55.5 
[52.25-67] 
57 [53-
65.75] 
p=0.84 58 [50-66.5] 58 [45-66] p=0.56 
BMI 30±5.4 25.1±2.3 p=0.03 32.2±4.3 25.9±1.9 p=0.003 
Sex 5m, 3f 5m, 3f  7m, 2f 4m, 3f  
ACEi/ ARB 8 (100) n/a  9 (100)  n/a  
BB 6 (75) n/a  7 (78) n/a  
MRA 5 (63) n/a  8 (89) n/a  
Digoxin 1 (13) n/a  4 (44) n/a  
Loop diuretic 
6 (75) n/a 
 
6 (67) n/a 
 
Haemoglobin 
(visit 1 vs 
visit 2, g/L) 
n/a n/a  136.0±14.46 
vs 
133.0±14.96 
(p>0.99) 
 
143.7±7.111 
vs         
135.3±8.524 
(p>0.99) 
 
 
Creatinine 
(visit 1 vs 
visit 2, 
μmol/L) 
n/a n/a  109.8±39.66 
vs 
116.3±74.95 
(p>0.99) 
 
75.29±8.635 
vs 
72.67±7.840 
(p>0.99) 
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Table 2: Results of Systemic Infusion of Urocortin 2 and 3. 
 
Healthy Volunteers Urocortin 2 Urocortin 3  SNP 
Cardiac Index +11.9 [-3.1 to +26.9] 
p=0.17 
+25.4 [+9.8 to 
+41.0]*** 
+21.7 [+5.5 to 
+37.8]** 
Heart Rate +17.2 [+7.2 to 
+27.1]*** 
+25.0 [+14.7 to 
+35.4]**** 
+29.0 [+18.4 to 
+39.8]**** 
MAP -8.0 [-2.6 to -13.5] ** -10.8 [-5.1 to -
16.4]**** 
-13.0 [-7.2 to -18.8] 
**** 
SV -3.7 [-13.8 to +6.4] 
p=0.77 
-6.3 [-16.9 to +4.2] 
p=0.40 
-6.8 [-17.4 to +3.9] 
p=0.35  
PVRI -17.6 [-3.5 to -
31.7]** 
-23.1 [-8.4 to -
37.8]*** 
-22.1 [-6.9 to -
37.3]** 
Heart Failure    
Cardiac Index +10.1 [+1.0 to +19.3] 
* 
+23.5 [+14.3 to 
+32.7] **** 
+14.2 [+3.8 to 
+24.7]** 
Heart Rate +7.1 [-0.8 to +15.0] 
p=0.1 
+18.1 [+10.0 to 
+26.3] **** 
+7.4 [-1.8 to +16.6] 
p=0.16 
MAP -4.8 [-0.5 to -9.0] * -9.1 [-4.8 to -13.5] 
**** 
-13.6 [-8.7 to -
18.5]**** 
SV +2.7 [-2.4 to +7.8] 
p=0.51 
+4.3 [-0.9 to +9.5] 
p=0.14 
+0.7 [-4.8 to +6.3] 
p=0.99 
PVRI -14.0 [-5.3 to -22.7] 
*** 
-25.2 [-16.2 to -34.2] 
**** 
-22.1 [-12.2 to -
32.0]**** 
    
 
 
 
Mean difference [95%CI] of each agent with saline placebo across the 3 administered doses. 
* represents significant differences with placebo. (****=p<0.0001, ***=p<0.001, **=p<0.01, 
*=p<0.05).  
 
 
